U.S. Markets close in 5 hrs 33 mins

CEL-SCI Corporation (NYSE MKT: CVM) is Selected as Bob Flaherty's Personal Pick in Flaherty's 35th Annual Favorites of the Famous: Ten Stocks for Tomorrow!

WEST HARRISON, NY / ACCESSWIRE / April 13, 2016 / CEL-SCI Corporation (NYSE MKT: CVM) was selected as Editor Bob Flaherty's own single favorite stock in the current April 6th issue of "The 35th Annual Flaherty's Favorites of the Famous: Ten Stocks for Tomorrow!" The feature is archived on our website at http://www.flahertyfinancialnews.com/ .

Four decades ago Bob launched Forbes' "If You Could Love Only One..." There famous money men picked their single favorite stock for the next year. A form of it still is published by Forbes each year. As editor of Equities Magazine for 25 years until he retired, Bob continued the feature and the portfolio of his stock pickers racked up the best long-run print record for a feature of this kind anywhere in the world.

At totally online Flaherty Financial News "If You Could Love Only One..." continues on with the help of our friends: Tom Putnam goes banking. Mario Gabelli bets on a new CEO. Arun Pudur cleans up India. John Rogers Jr. likes Zebra stripes. Lauren Templeton and hubby Scott Phillips team up again. Russ Cleveland is stubborn. Doug Makepeace doubles down on his Putin pal P/E of 3 Blood-In-The-Streets Russian pick. Bob sticks with his mother of all biotech credibility gaps.

Why did Bob choose CEL-SCI as his favorite? CEL-SCI is the first company in the world to administer its Phase III immune system boosting drug at the most logical time. It administers it's Multikine when the immune system is still strongest, before surgery, radiation and chemotherapy. Success in this study should have a significant impact on improving patient survival.

Administering immunotherapy treatment earlier makes common sense. A healthy immune system should be able to kill more cancer cells than an anemic debilitated one. Phase III results are expected in about 2 years when the 300th enrolled patient in the two main comparison groups dies. Only then can survival results be measured. A 10% improvement in overall patient survival versus the current standard of cancer care is the goal. Success would add billions to the stock valuation. Only two years to the finish line!

Direct Server Link to Flaherty Financial Newsletter #56: Favorites of the Famous - With the Modern Social Share Buttons:

http://campaign.r20.constantcontact.com/render?m=1101855435216&ca=32bbc1fc-0859-4828-ba7a-8b141e8a35b6

About Flaherty Financial News Inc.

Flaherty Financial News Inc. ("FFN") is the publisher of totally-electronic coverage of promising public companies. FFN was launched in 2007 by the "legendary financial editor" Bob Flaherty, Editor and Chairman of Flaherty Financial News Inc., and his son Brian, President and Publisher. While previously serving as Chairman and Editor of Equities Magazine for twenty-five years and also Editor-in-Chief of Equities Special Situations, Bob had one of the most consistent and highest ranked long-run performance records measured by Hulbert Financial Digest. He is also an award-winning retired Senior Editor of Forbes Magazine, where he wrote 33 cover stories, two shy of the all-time Forbes record. He was also Chairman of The Over-The-Counter Securities Fund. Bob Flaherty is a Magna Cum Laude graduate of Harvard College in economics and also has an MBA with a Distinction in Finance from Harvard Business School. A former president of the New York Financial Writers' Association, Bob is a co-founder of their annual student scholarship program and their annual award for significant long-term achievement in financial journalism.

About CEL-SCI Corporation.

CEL-SCI's work is focused on finding the best way to activate the immune system to fight cancer and infectious diseases. Its lead investigational immunotherapy Multikine (Leukocyte Interleukin, injection) is currently being studied in a pivotal Phase III clinical trial as a potential neo-adjuvant treatment for patients with squamous cell carcinoma of the head and neck. If the study endpoint, which is a 10% improvement in overall survival of the subjects treated with the Multikine treatment regimen plus the current standard of care as compared to subjects treated with the current standard of care only is satisfied, the study results will be used to support applications that CEL-SCI plans to submit to regulatory agencies in order to seek commercial marketing approvals for Multikine in major markets around the world. Additional clinical indications for Multikine that are being investigated include the treatment of cervical dysplasia in HIV/HPV co-infected women, and the treatment of peri-anal warts in HIV/HPV co-infected men and women. A Phase I trial of the former indication has been completed at the University of Maryland. The latter indication is now in a Phase I trial in conjunction with the U.S. Naval Medical Center, San Diego, under a CRADA (Cooperative Research and Development Agreement) and at the University of California, San Francisco.

Forward-Looking Statements:

This news release contains "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of l995) regarding Editor Bob Flaherty's personal pick of on CEL-SCI Corporation in our 35th Annual Flaherty's Favorites of the Famous issue and its future business plans. These statements involve known and unknown risks and uncertainties, which may cause actual results and future achievements to be materially different than those implied by these forward-looking statements. Flaherty Financial News Inc. and CEL-SCI Corporation have and undertake no obligation to provide public updates and revisions to these forward-looking statements to reflect any changes in their expectations of future events. Our full disclaimer and safe harbor statement appears in our Flaherty Financial News Newsletter #56.

Contact:

Flaherty Financial News Inc.
Robert J. Flaherty, Editor and Chairman
Phone: (914) 831-1151
http://www.flahertyfinancialnews.com

SOURCE: Flaherty Financial News Inc.